Clarity Pharmaceuticals announced that the US FDA has granted fast track designation for 64Cu-SAR-bisPSMA for positron emission tomography imaging of prostate-specific membrane antigen (PSMA) positive prostate cancer lesions.
[Clarity Pharmaceuticals]